Thieme : Inhaltsverzeichnis zu Hörl/Wanner : Dialyseverfahren in Klinik und Praxis, ISBN 313-49770-60

	Hörl/Wanner: Dialyseverfahren in Klinik und Praxis, ISBN: 3313-497706-0	[zurück]

Inhaltsverzeichnis

42 Renale Osteopathie und Störungen des Calcium-Phosphat-Stoffwechsels

H. Reichel

Akiba T, Marumo F, Owada A., et al. Controlled trial of falecalcitriol versus alfacalcidol in suppression of parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis. 1998;32:238-46.
Akizawa T, Kinugasa E, Kurihara S, et al. Parathyroid hormone deficiency is an indicator of poor nutritional state and prognosis in dialysis patients. J Am Soc Nephrol. 1999;10:615A.
Alfrey AC, LeGendre GR, Kaehny WD. The dialysis encephalopathy syndrome. Possible aluminum intoxication. N Engl J Med. 1976;294:184-8.
Almaden Y, Canalejo A, Hernandez A, et al. Direct effect of phosphorus on PTH secretion from whole rat parathyroid glands in vitro. J Bone Miner Res. 1996;11:970-6.
Almaden Y, Hernandez A, Torregrosa V, et al. High phosphate level directly stimulates parathyroid hormone secretion and synthesis by human parathyroid tissue in vitro. J Am Soc Nephrol. 1998;9:1845-52.
Amann K, Tornig J, Flechtenmacher C, Nabokov A, Mall G, Ritz E. Blood-pressure-independent wall thickening of intramyocardial arterioles in experimental uraemia - evidence for a permissive action of PTH. Nephrol Dial Transplant. 1995;10:2043-8.
Amann K, Ritz C, Adamczak M, Ritz E. Why is coronary heart disease of uraemic patients so frequent and so devastating? Nephrol Dial Transplant. 2003;18:631-40.
Amann K, Tornig J, Kugel B, et al. Hyperphosphatemia aggravates cardiac fibrosis and microvascular disease in experimental uremia. Kidney Int. 2003;63:1296-1301.
Andress DL, Endres DB, Maloney NA, Kopp JB, Coburn JW, Sherrard DJ. Comparison of parathyroid hormone assays with bone histomorphometry in renal osteodystrophy. J Clin Endocrinol Metab. 1986;63:1163-9.
Andress DL, Norris KC, Coburn JW, Slatopolsky E, Sherrard DJ. Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med. 1989;5:274-9.
Aparicio M, Combe C, Lafage MH, de Precigout V, Potaux L, Bouchet JC. In advanced renal failure, dietary phosphorus restriction reverses hyperthyroidism independent of changes in the levels of calcitriol. Nephron. 1993;63:122-3.
Argiles A, Kerr PG, Canaud B, Flavier JL, Mion C. Calcium kinetics and the long-term effects of lowering dialysate calcium concentration. Kidney Int. 1993;43:630-40.
Argiles A, Mourad G. How do we have to use the calcium in the dialysate to optimize the management of secondary hyperparathyroidism? Nephrol Dial Transplant. 1998;13[Suppl3]:62-4.
Arnold A, Brown MF, Urena P, Gaz RD, Safarti E, Drüeke TB. Monoclonality of parathyroid tumors in chronic renal failure and in primary parathyroid hyperplasia. J Clin Invest. 1995;95:2047-54.
Atsumi K, Kushida K, Yamazaki K, Shimizu S, Ohmura A, Inoue T. Risk factors for vertebral fractures in renal osteodystrophy. Am J Kidney Dis. 1999;33:287-293.
Aubia J, Serrano S, Marinoso L, et al. Osteodystrophy of diabetics in chronic dialysis: a histomorphometric study. Calcif Tissue Int. 1988;42:297-301.
Avbersek-Luznik I, Malesic I, Rus I, Marc J. Increased levels of osteoprotegerin in hemodialysis patients. Clin Chem Lab Med. 2002;40:1019-23.
Avram MM, Sreedhara R, Avram DK, Muchnick RA, Fein P. Enrollment parathyroid hormone level is a new marker of survival in hemodialysis and peritoneal dialysis therapy for uremia. Am J Kidney Dis. 1996;28:924-30.
Avram MM, Mittman N, Myint MM, Fein P. Importance of low serum intact parathyroid hormone as a predictor of mortality in hemodialysis and peritoneal dialysis patients - 14 years of prospective observation. Am J Kidney Dis. 2001;38:1351-7.
Baker LRI, Muir JW, Sharman VL, et al. Controlled trial of calcitriol in hemodialysis. Clin Nephrol. 1986;26:185-91.
Baker LRI, Abrams SML, Roe CJ, et al. 1,25(OH)2D3 administration in moderate renal failure - A prospective double-blind trial. Kidney Int. 1989;35:661-9.
Basu A, Chakrabarty K, Chatterjee GC. Neurotoxicity of lanthanum chloride in newborn chicks. Toxicol Lett. 1982;14:21-5.
Bayard F, Bec P, Ton That H, Louvet JP. Plasma 25-hydroxycholecalciferol in chronic renal failure. Europ JClin Invest. 1973;3:447-50.
Bekker PJ, Holloway D, Nakanishi A, Arrighi M, Leese PT, Dunstan CR. The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res. 2001;16:348-60.
Berl T, Berns AS, Huffer WE, et al. 1,25-Dihydroxycholecalciferol effects in chronic dialysis. Ann Int Med. 1978;88:774-80.
Bertoli M, Luisetto G, Ruffatti A, Urso M, Romagnoli G. Renal function during calcitriol therapy in renal failure. Clin Nephrol. 1990;33:98-102.
Bianchi ML, Colantonio G, Campanini F, et al. Calcitriol and calcium carbonate therapy in early chronic renal failure. Nephrol Dial Transplant. 1994;9:1595-9.
Bichara M, Mercier O, Borensztein P, Paillard M. Acute metabolic acidosis enhances circulating parathyroid hormone, which contributes to the renal response against acidosis in the rat. J Clin Invest. 1990;86:430-43.
Bittar AE, Ratcliffe PJ, Richardson AJ, Brown RC, Woodhead JS, Morris RJ. Hyperparathyroidism, hypertension and loop diuretic medication in renal transplant recipients. Nephrol Dial Transplant. 1989;4:740-4.
Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension. 2001;38:938-42.
Blind E, Schmidt-Gayk H, Scharla S, et al. Two site assay of intact parathyroid hormone in the investigation of primary hyperparathyroidism and other disorders of calcium metabolism compared with a midregion assay. J Clin Endocrin Metab. 1988;67:353-60.
Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients - a national study. Am J Kidney Dis. 1998;31:607-17.
De Boer IH, Gorodetskaya I, Young B, Hsu CY, Chertow GM. The severity of secondary hyperparathyroidism in chronic renal insufficiency is GFR-dependent, race-dependent, and associated with cardiovascular disease. J Am Soc Nephrol. 2002;13:2762-9.
De Broe ME, D'Haese PC, Couttenye MM, Van Landeghem GF, Lamberts LV. New insights and strategies in the diagnosis and treatment of aluminium overload in dialysis patients. Nephrol Dial Transplant. 1993;8[Suppl1]:47-50.
De Broe ME. Fosrenol (Lanthanum carbonate) vs calcium carbonate for the treatment of hyperphosphatemia - A comparison of the effects on bone using biopsy examination. J Am Soc Nephrol. 2002;13:769A.
Bogin E, Massry SG, Harary I. Effect of parathyroid hormone on rat heart cells. J Clin Invest. 1981;67:1215-27.
Bonifacio DL, Malineni K, Kadakia RA, Soman SS, Sandberg KR, McCullough PA. Coronary calcification and cardiac events after percutaneous intervention in dialysis patients. J Cardiovasc Risk. 2001;8:133-7.
Bothe V, Schmidt-Gayk H, Armbruster PP, Mayer E. Assay for the diagnosis of hyper- and hypovitaminosis D Ärztl Lab. 1984;30:151-6.
Brandi L, Egfjord M, Olgaard K. Pharmacokinetics of 1,25(OH)2D3 and 1alpha(OH)D3 in normal and uraemic men. Nephrol Dial Transplant. 2002;17;829-42.
Braun J, Oldendorf M, Moshage W, Heidler R, Zeitler E, Luft FC. Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis. 1996;27:394-401.
Bricker NS, Slatopolsky E, Reiss E, Avioli LV. Calcium, phosphorus, and bone in renal disease and transplantation. Arch Int Med. 1969;123:543-50.
Briner W, Rycek RF, Moellenberndt A, Dannull K. Neurodevelopmental effects of lanthanum in mice. Neurotoxicol Teratol. 2000;22:573-81.
Bro S, Olgaard K. Effects of excess PTH on nonclassical target organs. Am J Kidney Dis. 1997;30:606-20.
Brossard JH, Cloutier M, Roy L, Lepage R, Gascon-Barré M, D'Amour P. Accumulation of a non-(1-84) molecular form of parathyroid hormone (PTH) detected by intact PTH assay in renal failure - Importance in the interpretation of PTH values. J Clin Endocrinol Metab. 1996;81:3923-9.
Brossard JH, Lepage R, Cardinal H, et al. Influence of glomerular filtration rate on non-(1-84) parathyroid hormone (PTH) detected by intact PTH assays. Clin Chem. 2000;46:697-703.
Brown AJ, Slatopolsky E. Mechanisms for the selective actions of vitamin D analogs. In: Feldman D. Vitamin D. San Diego: Academic Press; 1997:995-1009.
Brown EM, Wilson RE, Eastman RC, Pallotta J, Marynick SP. Abnormal regulation of parathyroid hormone release in secondary hyperparathyroidism due to chronic renal failure. J Clin Endocrinol Metab. 1982;54:172-9.
Brown EM, Gamba G, Riccardi D, et al. Cloning and characterization of an extracellular Ca2+-sensing receptor from bovine parathyroid. Nature. 1993;366:575-80.
Brown EM, MacLeod RJ. Extracellular calcium sensing and extracellular calcium signaling. Physiol Rev. 2001;81:239-97.
Bucay N, Sarosi I, Dunstan CR, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998;12:1260-8.
Bushinsky DA. Effects of metabolic and respiratory acidosis on bone. Curr Opin Nephrol Hypertens. 1993;2:588-96.
Canalejo A, Almaden Y, Torregrosa V, et al. The in vitro effect of calcitriol on parathyroid cell proliferation and apoptosis. J Am Soc Nephrol. 2000;11:1865-72.
Cannata JB, Diaz Lopez JB. Insights into the complex aluminium and iron relationship. Nephrol Dial Transplant. 1991;6:605-7.
Carling T, Kindmark A, Hellman P, Holmberg L, Akerstrom G, Rastad J. Vitamin D receptor alleles b, a, and T: Risk factors for sporadic primary hyperparathyroidism (HPT) but not HPT of uremia or MEN1. Biochem Biophys Res Commun. 1997;231:329-32.
Cavatorta F, Delfino G, Solar P, Vagge R, Queirolo C. L'uso del diclorometilendifosfonato nel trattamento dell'osteodistrofia uremica: dati preliminari. G Ital Nefrol. 1989;6:135.
Charhon SA, Delmas PD, Malaval P, et al. Serum bone Gla-protein in renal osteodystrophy - comparison with bone histomorphometry. J Clin Endocrinol Metab. 1986;63:892-7.
Chen NX, O'Neill KD, Duan D, Moe SM. Phosphorus and uremic serum up-regulate osteopontin expression in vascular smooth muscle cells. Kidney Int. 2002;62:1724-31.
Chertow GM, Dillon M, Burke SK, et al. A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium - Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients. Clin Nephrol. 1999;51:18-26.
Chertow GM, Burke SK, Raggi P, et al. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002;62:245-52.
Chudek J, Ritz E, Kovacs G. Genetic abnormalities in parathyroid nodules of uremic patients. Clin Cancer Res. 1998;4:211-4.
Coburn JW, Maung HM. Calcimetic agents and the calcium-sensing receptor. Curr Opin Nephrol Hypertens. 2000;9:123-32.
Coe FL, Canterbury JM, Firpo JJ, Reiss E. Evidence for secondary hyperparathyroidism in idiopathic hypercalciuria. J Clin Invest. 1973;52:134-42.
Coen G, Mazzaferro S, Bonucci E, et al. Treatment of secondary hyperparathyroidism of predialysis chronic renal failure with low doses of 1,25(OH)2D3 - Humoral and histomorphometric results. Mineral Electrolyte Metab. 1986;12:375-82.
Coen G, Mazzaferro S, Ballanti P, et al. Procollagen type I C-terminal extension peptide in predialysis chronic renal failure. Am J Nephrol. 1992;12:246-51.
Coen G, Ballanti P, Mazzaferro S, Pasquali M, Bonucci E. Procollagen type 1 C-terminal extension peptide, PTH and 1,25(OH)2D3 in chronic renal failure. Bone. 1993;14:415-20.
Coen G, Mazzaferro S, Ballanti P, et al. Renal bone disease in 76 patients with varying degrees of predialysis chronic renal failure - a cross-sectional study. Nephrol Dial Transplant. 1996;11:813-9.
Coen G, Ballanti P, Bonucci E, et al. Bone markers in the diagnosis of low turnover osteodystrophy in haemodialysis patients. Nephrol Dial Transplant. 1998;13:2294-302.
Coen G, Bonucci E, Ballanti P, et al. PTH 1-84 and PTH "7-84" in the noninvasive diagnosis of renal bone disease. Am J Kidney Dis. 2002;40:348-54.
Coen G, Ballanti P, Balducci A, et al. Serum osteoprotegerin and renal osteodystrophy. Nephrol Dial Transplant. 2002;17:233-8.
Cohen Solal ME, Sebert JL, Boudaillez B, et al. Comparison of intact, midregion, and carboxyterminal assays of parathyroid hormone for the diagnosis of bone disease in hemodialyzed patients. J Clin Endocrinol Metab. 1991;73:516-24.
Collins MT, Skarulis MC, Bilezikian JP, Silverberg SJ, Spiegel AM, Marx SJ. Treatment of hypercalcemia secondary to parathyroid carcinoma with a novel calcimimetic agent. J Clin Endocrinol Metab. 1998;83:1083-8.
Couttenye MM, D'Haese PC, Van Hoof VO, et al. Low serum levels of alkaline phosphatase of bone origin - a good marker of adynamic bone disease in hemodialysis patients. Nephrol Dial Transplant. 1996;11:1065-72.
Couttenye MM, D'Haese PC, Deng JT, Van Hoof VO, Verpooten GA, De Broe ME. High prevalence of adynamic bone disease diagnosed by biochemical markers in a wide sample of the European CAPD population. Nephrol Dial Transplant. 1997;12:2144-50.
Cozzolino M, Lu Y, Finch JL, Slatopolsky E, Dusso AS. P21 waf1 and TGF-alpha mediate parathyroid growth arrest by vitamin D and high calcium. Kidney Int. 2001;60:2109-17.
Cushner HM, Copley JB, Lindberg JS, Foulks CJ. Calcium citrate, a nonaluminum-containing phosphate-binding agent for treatment of CRF. Kidney Int. 1988;33:95-9.
Davies MR, Hruska KA. Pathophysiological mechanisms of vascular calcification in end-stage renal disease. Kidney Int. 2001;60:472-9.
Delling G. Morphologie und Klassifikation der renalen Osteopathie. In: Ritz E. 1,25-Dihydroxy-Vitamin D3 - Produktmonographie. Stuttgart: Schattauer; 1996:73-94.
Delmez JA, Tindira C, Grooms P, Dusso A, Windus DW, Slatopolsky E. Parathyroid suppression by intravenous 1,25-dihydroxyvitamin D. J Clin Invest. 1989;83:1349-55.
Delmez JA, Kelber J, Norword KY, Giles KS, Slatopolsky E. Magnesium carbonate as a phosphorus binder - a prospective, controlled, crossover study. Kidney Int. 1996;49:163-7.
Demay MB, Kiernan MS, DeLuca HF, Kronenberg HM. Sequences in the human parathyroid hormone gene that bind the 1,25 dihydroxyvitamin D3 receptor and mediate transcriptional repression in response to 1,25-dihyroxyvitamin D3. Proc. Natl Acad Sci USA. 1992;89:8097-101.
Diaz-Corte S, Diaz M, Alonso C, Barreto S, Andia J. Prevention, diagnosis and treatment of renal osteodystrophy in Spain - Preliminary results from a multicentre enquiry. Nephrol Dial Transplant. 1998;13:51-6.
Dimkovic NB, Bargman J, Vas S, Oreopoulos DG. Normal or low initial PTH levels are not a predictor of morbidity/mortality in patients undergoing chronic peritoneal dialysis. Perit Dial Int. 2002;22:204-10.
Divieti P, Inomata N, Chapin K, et al. Receptors for the carboxy-terminal region of PTH(1-84) are highly expressed in osteocytic cells. Endocrinology. 2001;142:916-25.
Dobolyi A, Ueda H, Uchida H, Palkovits M, Usdin TB. Anatomical and physiological evidence for involvement of tuberoinfundibular peptide of 39 residues in nociception. Proc Natl Acad Sci USA. 2002;99:1651-6.
Drachman R, Baillet G, Gagnadoux MF, de Vernejoul P, Broyer M. Pulmonary calcifications in children on dialysis. Nephron. 1986;44:46-50.
Drüeke TB. The pathogenesis of parathyroid gland hyperplasia in chronic renal failure. Kidney Int. 1995;48:259-72.
Drüeke TB, Cunningham J, Goodman WG, et al. Short-term treatment of secondary hyperparathyroidism (SHPT) with the calcimimetic agent AMG 073. J Am Soc Nephrol. 2001;12:764A.
Drüeke TB. Parathyroid gland hyperplasia in uermia. Kidney Int. 2001;59:1182-3.
Drüeke TB, Eckardt KU. Role of secondary hyperparathyroidism in erythropoietin resistance of chronic renal failure patients. Nephrol Dial Transplant. 2002;17[Suppl5]:28-31.
Dusso A, Lopez-Hilker S, Rapp N, Slatopolsky E. Extra-renal production of calcitriol in chronic renal failure. Kidney Int. 1988;34:368-75.
Dusso AS, Brown AJ. Mechanism of vitamin D action and its regulation. Am J Kidney Dis. 1998;32[Suppl2]:13-24.
Dusso AS, Pavlopoulos T, Naumovich L, et al. p21 waf1 and TGF-alpha mediate dietary phosphate regulation of parathyroid cell growth. Kidney Int. 2001;59:855-65.
Eguchi S, Hirata Y, Imai T, et al. Endothelin receptors in human parathyroid gland. Biochem. Biophys Res Commun. 1992;184:1448-55.
Estepa JC, Aguilera-Tejero E, Lopez I, Almaden Y, Rodriguez M, Felsenfeld AJ. Effect of phosphate on parathyroid hormone secretion in vivo. J Bone Miner Res. 1999;14:1848-54.
European Dialysis and Transplant Association. Proceedings of the European Dialysis and Transplant Association - Combined report on regular dialysis and transplantation in Europe IX. 1978.
European Dialysis and Transplant Association. Proceedings of the European Dialysis and Transplant Association - Combined report on regular dialysis and transplantation in Europe XIV. 1989.
Fajtova VT, Sayegh MH, Hickey N, Aliabadi P, Lazarus JM, LeBoff MS. Intact parathyroid hormone levels in renal insufficiency. Calcif Tissue Int. 1995;57:329-35.
Falchetti A, Bale AE, Amorosi A, et al. Progression of uremic hyperparathyroidism involves allelic loss on chromosome 11. J Clin Endocrinol Metab. 1993;76:139-44.
Fan SL, Cunningham J. Bisphosphonates in renal osteodystrophy. Curr Opin Nephrol Hypertens. 2001;10:581-8.
Farnebo F, Teh BT, Dotzenrath C, et al. Differenzial loss of heterozygosity in familial, sporadic, and uremic hyperparathyroidism. Hum Genet. 1997;99:342-9.
Felsenfeld AJ, Rodriguez M, Dunlay R, Llach F. A comparison of parathyroid gland function in haemodialysis patients with different forms of renal osteodystrophy. Nephrol Dial Transplant. 1991;6:244-51.
Fernandez E, Montoliu J. Successful treatment of massive uraemic tumoral calcinosis with daily haemodialysis and very low calcium dialysate. Nephrol Dial Transplant. 1994;9:1207-9.
Fernandez E, Fibla J, Betriu A, Piulats JM, Almirall J, Montoliu J. Association between vitamin D receptor gene polymorphisms and relative hypoparathyroidism in patients with chronic renal failure. J Am Soc Nephrol. 1997;8:1546-52.
Ferreira A, Simon P, Drüeke TB, Descamps-Latscha B. Potential role of cytokines in renal osteodystrophy. Nephrol Dial Transplant. 1996;11:399-400.
Fine A, Cox D, Fontaine B. Elevation of serum phosphate affects parathyroid hormone levels in only 50% of hemodialysis patients, which is unrelated to changes in serum calcium. J Am Soc Nephrol. 1993;3:1947-53.
Fine A, Zacharias J. Calciphylaxis is usually non-ulcerating: risk factors, outcome and therapy. Kidney Int. 2002;61:2210-7.
Fisher ER, Harris DCH. Comparison of intermittent oral and intravenous calcitriol in hemodialysis patients with secondary hyperparathyroidism. Clin Nephrol. 1993;40:216-20.
Fletcher S, Jones RG, Rayner HC, et al. Assessment of renal osteodystrophy in dialysis patients: use of bone alkaline phosphatase, bone mineral density and parathyroid ultrasound in comparison with bone histology. Nephron. 1997;75:412-9.
Floege J, Burchert W, Brandis A, et al. Imaging of dialysis-related amyloid (AB-amyloid) deposits with 131I-beta 2-microglobulin. Kidney Int. 1990;38:1169-76.
Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998;32[Suppl3]:S112-9.
Fournier A, Coevoet B, de Fremont JF, et al. Propranolol therapy for secondary hyperparathyroidism in uraemia. Lancet. 1978;2:50-1.
de Francisco AL, Amado JA, Cotorruelo JG, et al. Pulsatile-secretion of parathyroid hormone in patients with chronic renal failure. Clin Nephrol. 1993;39:224-8.
de Francisco AL, Cobo MA, Setien MA, et al. Effect of serum phosphate on parathyroid hormone secretion during hemodialysis. Kidney Int. 1998;54:2140-5.
de Francisco AL, Fresnedo GF, Rodrigo E, Pinera C, Amado JA, Arias M. Parathyroidectomy in dialysis patients. Kidney Int. 2002;80[Suppl]:161-6.
Fraser DR. Regulation of the metabolism of vitamin D. Physiol Rev. 1980;60:551-613.
Frazao JM, Elangovan L, Maung HM, et al. Intermittent doxercalciferol (1alpha-hydroxyvitamin D2) therapy for secondary hyperparathyroidism. Am J Kidney Dis. 2000;36:550-61.
Fujii Y, Tomic M, Stojilkovic SS, et al. Effects of endothelin-1 on Ca2+ signaling and secretion in parathyroid cells. J Bone Miner Res. 1995;10:716-25.
Fukagawa M, Kaname S, Igarashi T, Ogata E, Kurokawa K. Regulation of parathyroid hormone synthesis in chronic renal failure in rats. Kidney Int. 1991;39:874-81.
Fukagawa M, Akizawa T, Kurokawa K. Is aplastic osteodystrophy a disease of malnutrition? Curr Opin Nephrol Hypertens. 2000;9:363-7.
Fukuda N, Tanaka H, Tominaga Y, Fukagawa M, Kurokawa K, Seino Y. Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest. 1993;92:1436-43.
Gabay C, Ruedin P, Slosman D, et al. Bone mineral density in patients with end-stage renal failure. Am J Nephrol. 1993;13:115-23.
Gagne ER, Urena P, Leite-Silva S, et al.. Short- and long-term efficacy of total parathyroidectomy with immediate autografting compared with subtotal parathyroidectomy in hemodialysis patients. JAm Soc Nephrol. 1992;3:1008-17.
Gallieni M, Brancaccio D, Padovese P, et al. Low-dose intravenous calcitriol treatment of secondary hyperparathyroidism in hemodialysis patients. Kidney Int. 1992;42:1191-8.
Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serum PO4, Ca x PO4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol. 2001;12:2131-8.
Gao P, Scheibel S, D'Amour P, et al. Development of a novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone 1-84 - implications for improvement of accurate assessment of parathyroid function. J Bone Min Res. 2001;16:605-14.
Gerakis A, Hutchison AJ, Apostolou T, Freemont AJ, Billis A. Biochemical markers for non-invasive diagnosis of hyperparathyroid bone disease and adynamic bone in patients on haemodialysis. Nephrol Dial Transplant. 1996;11:2430-58.
Ghazali A, Fardellone P, Pruna A, et al. Is low plasma 25-(OH)vitamin D a major risk factor for hyperparathyroidism and Looser's zones independent of calcitriol? Kidney Int. 1999;55:2169-77.
Gogusev J, Duchambon P, Stoermann-Chopard C, Giovaninni M, Sarfati E, Drüeke TB: De novo expression of transforming growth factor-alpha in parathyroid gland tissue of patients with primary or secondary uraemic hyperparathyroidism. Nephrol Dial Transplant. 1996;11:2155-62.
Gogusev J, Duchambon P, Hory B, et al. Depressed expession of calcium receptor in parathyroid gland tissue of patients with primary or secondary uremic hyperparathyroidism. Kidney Int. 1997;51:328-36.
Gonzalez EA, Martin KJ. Coordinate regulation of PTH/PTHrP receptors by PTH and calcitriol in UMR106-01 osteoblast-like cells. Kidney Int. 1996;50:63-70.
Goodman WG, Duarte ME. Aluminum: effects on bone and role in the pathogenesis of renal osteodystrophy. Miner Electrolyte Metab. 1991;17:221-32.
Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000;342:1478-83.
Graham KA, Hoenich NA, Tarbit M, Ward MK, Goodship TH. Correction of acidosis in hemodialysis patients increases the sensitivity of the parathyroid glands to calcium. J Am Soc Nephrol. 1997;8:627-31.
Guerin AP, London GM, Marchais SJ, Metivier F. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant. 2000;15:1014-21.
Guillot AP, Hood VL, Runge CF, Gennari FJ. The use of magnesium-containing phosphate binders in patients with end-stage renal disease on maintenance hemodialysis. Nephron. 1982;30:114-7.
Gunther T, Chen ZF, Kim J, et al. Genetic ablation of parathyroid glands reveals another source of parathyroid hormone. Nature. 2000;406:199-203.
Haas M, Leko-Mohr Z, Roschger P, et al. Osteoprotegerin and parathyroid hormone as markers of high-turnover osteodystrophy and decreased bone mineralization in hemodialysis patients. Am J Kidney Dis. 2002;39:580-6.
Halleen J, Hentunen TA, Hellman J, Vaananen HK. Tartrate-resistant acid phosphatase from human bone: purification and development of an immunoassay. J Bone Miner Res. 1996;11:1444-52.
Halloran BP, Schaefer P, Lifschitz M, Levens M, Goldsmith RS. Plasma vitamin D metabolite concentrations in chronic renal failure - Effect of oral administration of 25-hydroxyvitamin D3. J Clin Endocrinol Metab. 1984;59:1063-9.
Hamdy NAT, McCloskey EV, Brown CB, Kanis JA. Effects of clodronate in severe hyperparathyroid bone disease in chronic renal failure. Nephron. 1990;56:6-12.
Hamdy NAT, Risteli J, Risteli L, et al. Serum type I procollagen peptide: a non-invasive index of bone formation in patients on haemodialysis. Nephrol Dial Transplant. 1994;9:511-6.
Hamdy NA, Kanis JA, Beneton MN, et al. Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. Brit Med J. 1995;310:358-63.
Hara S, Ubara Y, Arizono K, et al. Relation between parathyroid hormone and cardiac function in long-term hemodialysis patients. Miner Electrolyte Metab. 1995;21:72-6.
Heaf J. Causes and consequences of adynamic bone disease. Nephron. 2001;88:97-106.
Hercz G, Coburn JW. Prevention of phosphate retention and hyperphosphatemia in uremia. Kidney Int. 1987;22[Suppl]:S215-20.
Hercz G, Pei Y, Greenwood C, et al. Aplastic osteodystrophy without aluminum - The role of "suppressed" parathyroid function. Kidney Int. 1993;44:860-6.
Hercz G, Sherrard DJ, Chan W, Pei Y. Aplastic osteodystrophy - Follow-up after 5 years. J Am Soc Nephrol. 1994;5:851A.
Hergesell O, Ritz E. Phosphate binders on iron basis: a new perspective? Kidney Int. 1999;73[Suppl]:S42-5.
Hergesell O, Ritz E. Stabilized polynuclear iron hydroxide is an efficient oral phosphate binder in uraemic patients. Nephrol Dial Transplant. 1999;14:863-7.
Hernandez A, Concepcion MT, Rodriguez M, Salido E, Torres A. High phosphorus diet increases preproPTH mRNA independent of calcium and calcitriol in normal rats. Kidney Int. 1996;50:1872-8.
Hernandez D, Concepcion MT, Lorenzo V, et al. Adynamic bone disease with negative aluminium staining in predialysis patients - prevalence and evolution after maintenance dialysis. Nephrol Dial Transplant. 1994;9:517-23.
Herrmann P, Ritz E, Schmidt-Gayk H, et al. Comparison of intermittent and continuous oral administration of calcitriol in dialysis patients - A randomized prospective trial. Nephron. 1994;67:48-53.
Hofbauer LC, Schoppet M. Osteoprotegerin: a link between osteoporosis and arterial calcification? Lancet. 2001;358:257-9.
Holick MF, de Blanco MC, Clark MB, et al. The metabolism of [6-3H]1alpha, hydroxycholecalciferol to [6-3H]1alpha,25-dihydroxycholecalciferol in a patient with renal insufficiency. J Clin Endocrinol Metab. 1977;44:595-8.
Hruska K. New concepts in renal osteodystrophy. Nephrol Dial Transplant. 1998;13:2755-60.
Hsu CH, Patel SR, Young EW. New phosphate binding agents: ferric compounds. J Am Soc Nephrol. 1999;10:1274-80.
Hsu CH, Patel SR, Vanholder R. Mechanism of decreased intestinal calcctriol receptor concentration in renal failure. Am J Physiol. 1993;264:F662-9.
Huang JY, Huang CC, Lim PS, Wu MS, Leu ML. Effect of body iron stores on serum aluminum level in hemodialysis patients. Nephron. 1992;61:158-62.
Husdan H, Rapaprot A, Locke S. Influence of posture on the serum concentration of calcium. Metabolism. 1973;22:787-97.
Hutchinson AJ, Whitehouse RW, Boulton HF, et al. Correlation of bone histology with parathyroid hormone, vitamin D3, and radiology in end-stage renal failure. Kidney Int. 1993;44:1071-7.
Hutchison AJ, Whitehouse RW, Freemont AJ, Adams JE, Mawer EB, Gokal R. Histological, radiological, and biochemical features of the adynamic bone lesion in continuous ambulatory peritoneal dialysis patients. Am J Nephrol. 1994;14:19-29.
Hutchinson AJ. The novel, non-aluminium, non-calcium phosphate binder, fosrenol , is an effective treatment for hyperphosphatemia and has a good safety profile. J Am Soc Nephrol. 2002;13:385A-6A.
Imanishi Y, Hosokawa Y, Yoshimoto K, et al. Primary hyperparathyroidism caused by parathyroid-targeted overexpression of cyclin D1 in transgenic mice. J Clin Invest. 2001;107:1093-101.
Imanishi Y, Tahara H, Palanisamy N, et al: Clonal chromosomal defects in the molecular pathogenesis of refractory hyperparathyroidism of uremia. J Am Soc Nephrol. 2002;13:490-8.
Inaba M, Nagasue K, Okuno S, et al. Impaired secretion of parathyroid hormone, but not refractoriness of osteoblast, is a major mechanism of low bone turnover in hemodialyzed patients with diabetes mellitus. Am J Kidney Dis. 2002;39:1261-9.
Inagaki C, Dousseau M, Pacher N, Sarfati E, Drüeke TB, Gogusev J. Structural analysis of gene marker loci on chromosomes 10 and 11 in primary and secondary uraemic hyperparathyroidism. Nephrol Dial Transplant. 1998;13:350-7.
Indridason OS, Quarles LD. Oral versus intravenous calcitriol: is the route of administration really important? Curr Opin Nephrol Hypertens. 1995;4:307-12.
Inomata N, Akiyama M, Kubota N, Jüppner H. Characterization of a novel PTH-receptor with specificity for the carboxyl-terminal region of PTH(1-84). Endocrinology. 1995;136:4732-40.
Ishimi Y, Russell J, Sherwood LM. Regulation by calcium and 1,25-dihydroxyvitamin D3 of cell proliferation and function of bovine parathyroid cells in culture. J Bone Miner Res. 1990;5:755-60.
Jahnen-Dechent W, Schafer C, Heiss A, Grotzinger J. Systemic inhibition of spontaneous calcification by the serum protein alpha 2-HS glycoprotein/fetuin. Z Kardiol. 2001;90[Suppl3]:47-56.
Jakoby MG, Semenkovich CF. The role of osteoprogenitors in vascular calcification. Curr Opin Nephrol Hypertens. 2000;9:11-15.
Jarava C, Armas JR, Salgueira M, Palma A, et al. Bone alkaline phosphatase isoenzyme in renal osteodystrophy. Nephrol Dial Transplant. 1996;11[Suppl3]:43-6.
Jensen PB, Rasmussen HB, Pedersen FB. Serum concentration of the aminopropeptide of type I procollagen in patients on haemo- and peritoneal dialysis. APMIS. 1997;105:371-7.
Joffe P, Cintin C, Ladefoged SD, Rasmussen SN. Pharmacokinetics of 1 alpha-hydroxycholecalciferol after intraperitoneal, intravenous and oral administration in patients undergoing peritoneal dialysis. Clin Nephrol. 1994;41:364-9.
Joffe P, Heaf JG, Hyldstrup L. Osteocalcin: A non-invasive index of metabolic bone disease in patients treated by CAPD. Kidney Int. 1994;46:838-46.
Joffe PJ, Heaf L, Jensen LT. Type I procollagen propeptide in patients on CAPD: its relationship with bone histology, osteocalcin, and parathyroid hormone. Nephrol Dial Transplant. 1995;10:1912-7.
John MR, Goodman WG, Gao P, et al. A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: implications for PTH measurements in renal failure. J Clin Endocrinol Metab. 1999;84:4287-90.
Jono S, McKee MD, Murry CE, et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res. 2000;87:E10-7.
Joy MS, Finn WF. Fosrenol , a novel non-calcium, non-aluminium,phosphate binder, has a good safety and efficacy profile in the long-term treatment of hyperphosphatemia in hemodialysis patients. J Am Soc Nephrol. 2002;13:386A.
Jüppner H, Abou-Samra AB, Freeman M, et al. A G protein-linked receptor for parathyroid hormone and parathyroid hormone-related peptide. Science. 1991;254:1024-6.
Jüppner H. Receptors for parathyroid hormone and parathyroid hormone-related peptide: exploration of their biological importance. Bone. 1999;25:87-90.
Kaji H, Suzuki M, Yano S, et al. Risk factors for hip fracture in hemodialysis patients. Am J Nephrol. 2002;22:325-31.
Kakuta T, Fukagawa M, Fujisaki T, et al. Prognosis of parathyroid function after successful percutaneous ethanol injection therapy guided by color Doppler flow mapping in chronic dialysis patients. Am J Kidney Dis. 1999;33:1091-9.
Kanesaka Y, Tokunaga H, Iwashita K, Fujimura S, Naomi S, Tomita K. Endothelin receptor antagonist prevents parathyroid cell proliferation of low calcium diet-induced hyperparathyroidism in rats. Endocrinology. 2001;142:407-13.
Katoh N, Nakayama M, Shigematsu T, et al. Presence of sonographically detectable parathyroid glands can predict resistance to oral pulsed-dose calcitriol treatment of secondary hyperparathyroidism. Am J Kidney Dis. 2000;35:465-8.
Kaye M. Parathyroid surgery in renal failure. Sem Nephrol. 1990:3;86-92.
Kaye M, Rosenthal L, Hill RO, Tabah RJ. Long-term outcome following total parathyroidectomy in patients with end-stage renal disease. Clin Nephrol. 1993;39:192-7.
Kazama JJ, Shigematsu T, Yano K, et al. Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure. Am J Kidney Dis. 2002;39:525-32.
Ketteler M, Bongartz P, Westenfeld R, et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis - a cross-sectional study. Lancet. 2003;361:827-33.
Kifor O, Moore FJ, Wang P, et al. Reduced immunostaining for the extracellular Ca2+-sensing receptor in primary and uremic secondary hyperparathyroidism. J Clin Endocrinol Metab. 1996;81:1598-1606.
Kifor O, Diaz R, Butters R, Kifor I, Brown EM. The calcium-sensing receptor is localized in caveolin-rich plasma membrane domains of bovine parathyroid cells. J Biol Chem. 1998;273:21708-13.
Kilav R, Silver J, Naveh-Many T. Parathyroid hormone gene expression in hypophosphatemia. J Clin Invest. 1995;96:327-33.
Kimura Y, Nakayama M, Kuriyama S, Watanabe S, Kawaguchi Y, Sakai O. Pharmacokinetics of active vitamins D3, 1 alpha-hydroxyvitamin D3 and 1 alpha, 25-dihydroxyvitamin D3 in patients on chronic hemodialysis. Clin Nephrol. 1991;35:72-7.
Kitaoka M, Fukagawa M, Ogata E, Kurokawa K. Reduction of functioning parathyroid cell mass by ethanol injection in chronic dialysis patients. Kidney Int. 1994;46:1110-7.
Kleeman CR. The role of chronic anion gap and/or nonion gap acidosis in the osteodystrophy of chronic renal failure in the predialysis era - A minority report. J Mineral Electrol Metab. 1994;20:81-96.
Kleerekoper M, Cruz C, Bernstein RS, Levin NW, Foreback CC, Parfitt AM. The phosphaturic action of PTH in the steady-state in patients. Adv Exper Med Biol. 1980;128:145-53.
Kong YY, Feige U, Sarosi I, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature. 1999;402:304-9.
Korzets Z, Magen H, Kraus L, Bernheim J. Total parathyroidectomy with autotransplantation in haemodialysed patients with secondary hyperparathyroidism-should it be abandoned? Nephrol Dial Transplant. 1987;2:341-6.
Krauz E, Falkiewicz K, Szewczyk Z, et al. Calcification of the mitral valve annulus and of the aortic valve in patients with transplanted kidneys. Transplant Proc. 1996;28:3483-4.
Kremer R, Bolivar I, Goltzman D, Hendy GN. Influence of calcium and 1,25-dihydroxycholecalciferol on proliferation and proto-oncogene expression in primary cultures of bovine parathyroid cells. Endocrinology. 1989;125:935-41.
Krukeja SC, Hargis GK, Bowser EN, Henderson WJ, Fisherman EW, Williams GA. Role of adrenergic stimuli in parathyroid hormone secretion in man. J Clin Endocrinol Metab. 1975;40:478-81.
Kurokawa K, Akizawa T, Suzuki M, Akiba T, Ogata E, Slatopolsky E. Effect of 22-oxacalcitriol on hyperparathyroidism of dialysis patients: results of a preliminary study. Nephrol Dial Transplant. 1996;11[Suppl3]:121-4.
Kurz P, Monier-Faugere MC, Bognar B, et al. Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int. 1994;46:855-61.
Kurz P, Tsobanelis T, Roth P, et al. Differences in calcium kinetic pattern between CAPD and HD patients. Clinical Nephrology 1995;44:255-61.
Kwan JTC, Almond MK, Beer JC, Noonan K, Evans SJW, Cunningham J. "Pulse" oral calcitriol in uraemic patients: rapid modification of parathyroid response to calcium. Nephrol Dial Transplant. 1992;7:829-34.
Lafage MH, Combe C, Fournier A, Aparicio M. Ketodiet, physiological calcium intake and native vitamin D improve renal osteodystrophy. Kidney Int. 1992;42:1217-25.
Lafage-Proust MH, Combe C, Barthe N, Aparicio M. Bone mass and dynamic parathyroid function according to bone histology in nondialyzed uremic patients after long-term protein and phosphorus restriction. J Clin Endocrinol Metab. 1999;84:512-9.
Langub MC, Koszewski NJ, Turner HV, Monier-Faugere MC, Geng Z, Malluche HH. Bone resorption and mRNA expression of IL-6 and IL-6 receptor in patients with renal osteodystrophy. Kidney Int. 1996;50:515-20.
Lee WT, Collins JF, Padayachi K, Cundy T. A comparison of oral and intravenous alfacalcidol in the treatment of uremic hyperparathyroidism. J Am Soc Nephrol. 1994;5:1344-8.
Lefebvre A, de Vernejoul MC, Gueris J, Goldfarb B, Graulet AM, Morieux C. Optimal correction of acidosis changes progression of dialysis osteodystrophy. Kidney Int. 1989;36:1112-8.
Lepage R, Roy L, Brossard JH, et al. PTH circulating fragment interferes significantly with intact PTH measurement by commercial assays in uremic samples. Clin Chem. 1998;44:805-9.
Li XQ, Tembe V, Horwitz GM, Bushinsky DA, Favus MJ. Increased intestinal vitamin D receptor in genetic hypercalciuric rats. J Clin Invest. 1993;91:661-7.
Lindberg JS, Moe SM, Goodman WG, et al. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney Int. 2003;63:248-54.
Lindberg JS, Moe SM. Osteoporosis in end-state renal disease. Semin Nephrol. 1999;19:115-22.
Liu SM, Koszewski N, Lupez M, Malluche HH, Olivera A, Russell J. Characterization of a response element in the 5'-flanking region of the avian (chicken) PTH gene that mediates negative regulation of gene transcription by 1,25-dihydroxyvitamin D3 and binds the vitamin D3 receptor. Mol Endocrinol. 1996;10:206-15.
Ljutic D, Cameron JS, Ogg CS, Turner C, Hicks JA, Owen WJ. Long-term follow-up after total parathyroidectomy without parathyroid reimplantation in chronic renal failure. Quart J Med. 1994;87:685-92.
Lobao R, Carvalho A, Cuppari L, Ajzen H. Low turnover bone disease detected by bone densitometry in predialysis chronic renal failure patients. J Am Soc Nephrol. 1996;11:11793A.
London GM. Left ventricular alterations and end-stage renal disease. Nephrol Dial Transplant. 2002;17:29-36.
Lopes-Hilker S, Dusso AS, Rapp NS, Martin KJ, Slatopolsky E. Phosphorus restriction reverses hyperparathyroidism in uremia independent of changes in calcium and calcitriol. Am J Physiol. 1990;259:F432-7.
Lopez Gavilanes E, Gonzalez Parra E, de la Piedra C, Caramelo C, Rapado A. Clinical usefulness of serum carboxyterminal propeptide of procollagen I and tartrate-resistant acid phosphatase determinations to evaluate bone turnover in patients with chronic renal failure. Miner Electrolyte Metab. 1994;20:259-64.
Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis. 1990;15:458-82.
Lu KC, Shieh SD, Li BL, Chu P, Jan SY, Lin YF. Rapid correction of metabolic acidosis in chronic renal failure: effect on parathyroid hormone activity. Nephron. 1994;67:419-24.
Lucas PA, Brown RC, Woodhead JS. Acute responses of parathyroid hormone and 1,25-dihydroxyvitamin D3 to unilateral nephrectomy in healthy donors. Nephrol Dial Transplant. 1986;1:199-203.
Lucas PA, Brown RC, Woodhead JS. Vitamin D3 metabolites in chronic renal failure and after renal transplantation. Nephrol Dial Transplant. 1988;3:70-6.
Lund RJ, Davies MR, Hruska KA. Bone morphogenetic protein-7: an anti-fibrotic morphogenetic protein with therapeutic importance in renal disease. Curr Opin Nephrol Hypertens. 2002;11:31-6.
Lundgren S, Carling T, Hjalm G, et al. Tissue distribution of human gp330/megalin, a putative Ca2+-sensing protein. J Histochem Cytochem. 1997;45:383-92.
Luo G, Ducy P, McKee MD, et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature. 1997;386:78-81.
Maher ER, Pazianas M, Curtis JR. Calcific aortic stenosis: a complication of chronic uraemia. Nephron. 1987;47:119-22.
Malberti F, Marcelli D, Conte F, Limido A, Spotti D, Locatelli F. Parathyroidectomy in patients on renal replacement therapy: an epidemiologic study. J Am Soc Nephrol. 2001;12:1242-8.
Mallette LE. The hypercalcemias. Sem Nephrol. 1992;12:159-90.
Malluche HH, Ritz E, Lange HP, et al. Bone histology in incipient and advanced renal failure. Kidney Int. 1976;9:355-62.
Malluche HH, Werner E, Ritz E. Intestinal absorption of calcium and whole-body calcium retention in incipient and advanced renal failure. Miner Electrolyte Metab. 1978;1:263-70.
Malluche HH, Faugere MC, Fanti P, Price PA. Plasma levels of bone GLA-protein reflect bone formation on chronic maintenance hemodialysis. Kidney Int. 1984;26:869-74.
Malluche HH, Matthews C, Faugere MC, Fant P, Endres DB, Friedler RM. 1,25-Dihydroxyvitamin D3 maintains bone cell activity, and parathyroid hormone modulates bone cell number in dogs. Endocrinology. 1986;119:1298-304.
Malluche HH, Faugere MC. Risk of adynamic bone disease in dialyzed patients. Kidney Int. 1992;42[Suppl]:S62-7.
Malyszko J, Wolczynski S, Zbroch E, Brzosko S, Malyszko J, Mysliwiec M. Serum crosslaps correlations with serum ICTP and urine DPD in hemodialyzed and peritoneally dialyzed patients. Nephron. 2001;87:283-5.
Marchais SJ, Metivier F, Guerin AP, London GM. Association of hyperphosphataemia with haemodynamic disturbances in end-stage renal disease. Nephrol Dial Transplant. 1999;14:2178-83.
Martin KJ, Gonzalez EA, Gellens M, Hamm LL, Abboud H, Lindberg J. 19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol. 1998;9:1427-32.
Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res. 2000;15:613-20.
Massry SG, Smogorzewski M. Mechanisms through which parathyroid hormone mediates its deleterious effects on organ function in uremia. Semin Nephrol. 1994;14:219-31.
Maung HM, Elangovan L, Frazao JM, et al. Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1alpha-hydroxyvitamin D2) in dialysis patients with secondary hyperparathyroidism: a sequential comparison. Am J Kidney Dis. 2001;37:532-43.
Mawad HW, Sawaya BP, Sarin R, Malluche HH. Calcific uremic arteriolopathy in association with low turnover uremic bone disease. Clin Nephrol. 1999;52:160-6.
Mazzaferro S, Coen G, Bandini S, et al. Role of ageing, chronic renal failure and dialysis in the calcification of mitral annulus. Nephrol Dial Transplant. 1993;8:335-40.
Mazzaferro S, Pasquali M, Ballanti P, et al. Diagnostic value of serum peptides of collagen synthesis and degradation in dialysis renal osteodystrophy. Nephrol Dial Transplant. 1995;10:52-8.
McGregor D, Burn J, Lynn K, Robson R. Rapid resolution of tumoral calcinosis after renal transplantation. Clin Nephrol. 1999;51:54-8.
McIntyre CW, Patel V, Taylor GS, Fluck RJ. A prospective study of combination therapy for hyperphosphataemia with calcium-containing phosphate binders and sevelamer in hypercalcaemic haemodialysis patients. Nephrol Dial Transplant. 2002;17:1643-8.
Memmos DE, Eastwood JB, Talner LB, et al. Double-blind trial of oral 1,25-dihydroxvitamin D3 versus placebo in asymptomatic hyperparathyroidism in patients receiving maintenance haemodialysis. Br Med J. 1981;282:1919-24.
Mendes V, Jorgetti V, Nemeth J, et al. Secondary hyperparathyroidism in chronic haemodialysis patients: A clinico-pathological study. Proc EDTA. 1983;20:731-6.
Milliner DS, Nebeker HG, Ott SM, et al. Use of the deferoxamine infusion test in the diagnosis of aluminum-related osteodystrophy. Ann Intern Med. 1984;101:775-9.
Mizumoto D, Watanabe Y, Fukuzawa Y, Yuzawa Y, Yamazaki C. Identification of risk factors on secondary hyperparathyroidism undergoing long-term haemodialysis with vitamin D3. Nephrol Dial Transplant. 1994;9:1751-8.
Moallem E, Kilav R, Silver J, Naveh-Many T. RNA-Protein binding and posttranscriptional regulation of parathyroid hormone gene expression by calcium and phosphate. J Biol Chem. 1998;273:5253-9.
Moe SM, O'Neill KD, Duan D, et al. Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins. Kidney Int. 2002;61:638-47.
Monier-Faugere M, Langub M, Malluche HH. Mineralized bone histology in normal and uremic states. In: Bushinsky DA. Renal osteodystrophy. Philadelphia: Lippincott Raven; 1998:49-87.
Monier-Faugere MC, Geng Z, Mawad H, et al. Improved assessment of bone turnover by the PTH-(1-84)/large C-PTH fragments ratio in ESRD patients. Kidney Int. 2001;60:1460-8.
Moriniere P, Maurouard C, Boudailliez B, et al. Prevention of hyperparathyroidism in patients on maintenance dialysis by intravenous 1-alpha-hydroxyvitamin D3 in association with Mg(OH)2 as sole phosphate binder. Nephron. 1992;60:154-63.
Morishita T, Nomura M, Hanaoka M, Saruta T, Matsuo T, Tsukamoto Y. A new assay method that detects only intact osteocalcin. Two-step non-invasive diagnosis to predict adynamic bone disease in haemodialysed patients. Nephrol Dial Transplant. 2000;15:659-67.
Morony S, Capparelli C, Sarosi I, Lacey DL, Dunstan CR, Kostenuik PJ. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res. 2001;61:4432-6.
Nakanishi S, Kazama JJ, Shigematsu T, et al. Comparison of intakt PTH assay and whole PTH assay in long-term dialysis patients. Am J Kidney Dis. 2001;38[Suppl1]:S172-4.
Nakasato YR, Janckila AJ, Halleen JM, Vaananen HK, Walton SP, Yam LT. Clinical significance of immunoassays for type-5 tartrate-resistant acid phosphatase. Clin Chem. 1999;45:2150-7.
Nappi SE, Saha HH, Virtanen VK, Mustonen JT, Pasternack AI. Hemodialysis with high-calcium dialysate impairs cardiac relaxation. Kidney Int. 1999;55:1091-6.
Naveh-Many T, Friedlaender MM, Mayer H, Silver J. Calcium regulates parathyroid hormone messenger ribonucleic acid (mRNA), but not calcitonin mRNA in vivo in the rat. Dominant role of 1,25-hihydroxyvitamin D. Endocrinology. 1989;125:275-80.
Negri AL, Quiroga MA, Bravo M, et al. Serum crosslaps as bone resorption marker in peritoneal dialysis. Perit Dial Int. 2002;22:628-30.
Nichols P, Owen JP, Ellis HA, Farndon JR, Kelly PJ, Ward MK. Parathyroidectomy in chronic renal failure: a nine-year follow-up study. Quart J Med. 1990;77:1175-93.
Niwa T, Shiobara K, Hamada T, et al. Serum pyridinolines as specific markers of bone resorption in hemodialyzed patients. Clin Chim Acta. 1995;235:33-40.
Nordal KP, Dahl E. Low dose calcitriol versus placebo in patients with predialysis chronic renal failure. J Clin Endocrinol Metab. 1988;5:929-36.
Nussbaum SR, Zahradnik RJ, Lavigne JR, et al. Highly sensitive two-site immunoradiometric assay for parathyrin and its clinical utility in evaluating patients with hypercalcemia. Clin Chem. 1987;33:1364-7.
Oe PL, Lips P, van der Meulen J, de Vries PM, van Bronswijk H, Donker AJ. Long-term use of magnesium hydroxide as a phosphate binder in patients on hemodialysis. Clin Nephrol. 1987;28:180-5.
Oh J, Wunsch R, Turzer M, et al. Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Circulation. 2002;106:100-5.
Ohta K, Manabe T, Katagiri M, Harada T. Expression of proliferating cell nuclear antigens of renal hyperparathyroidism. World J Surg. 1994;18:625-32.
Okabe R, Nakatsuka K, Inaba M, et al. Clinical evaluation of the Elecsys beta-CrossLaps serum assay, a new assay for degradation products of type I collagen C-telopeptides. Clin Chem. 2001;47:1410-4.
Olaizola I, Aznarez A, Jorgetti V, et al. Are there any differences in the parathyroid response in the different types of renal osteodystrophy? Nephrol Dial Transplant. 1998;13:15-8.
Olgaard K, Arbelaez M, Schwartz J, Klahr S, Slatopolsky E. Abnormal skeletal response to parathyroid hormone in dogs with chronic uremia. Calcif Tissue Int. 1982;34:403-7.
Ouseph R, Leiser JD, Moe SM. Calcitriol and the parathyroid hormone-ionized calcium curve: a comparison of methodologic approaches. J Am Soc Nephrol. 1996;497-505.
Ozono K, Sone T, Pike JW. The genomic mechanism of action of 1,25-dihydroxyvitamin D3. J Bone Miner Res. 1991;10:1021-7.
Palanisamy N, Imanishi Y, Rao PH, Tahara H, Chaganti RS, Arnold A. Novel chromosomal abnormalities identified by comparative genomic hybridization in parathyroid adenomas. J Clin Endocrinol Metab. 1988;83:1766-70.
Palmer RJ, Butenhoff JL, Stevens JB. Cytotoxicity of the rare earth metals cerium, lanthanum, and neodymium in vitro: comparisons with cadmium in a pulmonary macrophage primary culture system. Environ Res. 1987;43:142-56.
Panuccio V, Mallamaci F, Tripepi G, et al. Low parathyroid hormone and pentosidine in hemodialysis patients. Am J Kidney Dis. 2002;40:810-5.
Parfitt AM. Hypercalcemic hyperparathyroidism following renal transplantation: Differenzial diagnosis, management, and implications for cell population control in the parathyroid gland. Mineral Electrolyte Metab. 1982;8:92-112.
Payne RB, Carver ME, Morgan DB. Interpretation of serum total calcium: effects of adjustment for albumin concentration on frequency of abnormal values and on detection of change in the individual. J Clin Pathol. 1979;32:56-60.
Pei Y, Hercz G, Greenwood C, et al. Non-invasive prediction of aluminum bone disease in hemo- and peritoneal dialysis patients. Kidney Int. 1992;41:1374-82.
Pei Y, Hercz G, Greenwood C, et al. Risk factors for renal osteodystrophy: a multivariant analysis. J Bone Miner Res. 1995;10:149-56.
Petit WA, Henrich J, Insogna KL, Milnick ME, Broadus AE. Influence of furosemide on parathyroid hormone levels in hyperparathyroidism. N Engl J Med. 1988;318:644-5.
Picton ML, Moore PR, Mawer EB, et al. Down-regulation of human osteoblast PTH/PTHrP receptor mRNA in end-stage renal failure. Kidney Int. 2000;58:1440-9.
Pierratos A, Ouwendyk M, Francoeur R, et al. Nocturnal hemodialysis: three-year experience. J Am Soc Nephrol. 1998;9:859-68.
Piraino B, Chen T, Cooperstein L, Segre G, Puschett J. Fractures and vertebral bone mineral density in patients with renal osteodystrophy. Clin Nephrol. 1988;30:57-62.
Pogglitsch H, Estelberger W, Petek W, Zitta S, Ziak E. Relationship between generation and plasma concentration of anorganic phosphorus. In vivo studies on dialysis patients and in vitro studies on erythrocytes. Int J Artif Organs. 1989;12:524-32.
Portale AA, Boothe BE, Halloran BP, Morris jr RC. Effect of dietary phosphorus on circulating concentrations of 1,25-dihydroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency. J Clin Invest. 1984;73:1580-9.
Potts jr JT, Jüppner H. Parathyroid hormone and parathyroid hormone-related peptide in calcium homeostasis, bone metabolism, and bone development: the proteins, their genes, and receptors. In: Avioli LV, Crane SM. Metabolic Bone Disease. New York: Academic; 1997:51-94.
Qi Q, Monier-Faugere MC, Geng Z, Malluche HH. Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis. Am J Kidney Dis. 1995;26:622-31.
Quarles LD, Lobaugh B, Murphy G. Intact parathyroid hormone overestimates the presence and severity of parathyroid mediated osseous abnormalities in uremia. J Clin Endocrinol Metab. 1992;75:145-50.
Quarles LD, Yohay DA, Carrol BA, et al. Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD. Kidney Int. 1994;45:1710-21.
Quarles LD, Sherrard DJ, Adler S, et al. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol. 2003;14:575-83.
Raggi P, Boulay A, Chasan-Taber S, et al. Cardiac calcification in adult hemodialysis patients - A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol. 2002;39:695-701.
Ramirez JA, Goodman WG, Gornbein J, et al. Direct in vivo comparison of calcium-regulated parathyroid hormone secretion in normal volunteers and patients with secondary hyperparathyroidism. J Clin Endocrinol Metab. 1993;76:1489-94.
Ramirez JA, Goodman WG, Belin TR, Gales B, Segre GV, Salusky IB. Calcitriol therapy and calcium-regulated PTH secretion in patients with secondary hyperparathyroidism. Am J Physiol. 1994;267:E961-7.
Recker RR, Bammi A, Barger-Lux MJ, Heaney RP. Calcium absorbability from milk products, an imitation milk, and calcium carbonate. Am J Clin Nutr. 1988;47:93-5.
Reichel H, Koeffler HP, Norman AW. The role of the vitamin D endocrine system in health and disease. N Engl J Med. 1989;320:980-91.
Reichel H, Deibert B, Schmidt-Gayk H, Ritz E. Calcium metabolism in early chronic renal failure - Implications for the pathogenesis of hyperparathyroidism. Nephrol Dial Transplant. 1991;6:162-9.
Reichel H, Szabo A. The vitamin D endocrine system. Experimental and clinical findings related to vitamin D receptor expression and vitamin D-PTH interactions in health and in renal disease. Ital J Mineral Electrol Metab. 1993;7:1-8.
Reichel H, Benzing C. Pathogenese der renalen Osteopathie. Nieren- und Hochdruckkrankheiten. 1999;28:379-85.
Reichel H, Benzing C, Roth HJ, Schmidt-Gayk H. Assessment of risk factors and complications of adynamic bone disease (ABD) in hemodialysis (HD) patients. Kidney & Blood Press Res. 1999a;22:236.
Reichel H, Benzing C, Roth HJ, Schmidt-Gayk H. High correlation of serum tartrate resistant aicd phosphatase (TRAP) as measured by immunoassay with other markers of bone metabolism in hemodialysis (HD) patients. Kidney & Blood Press Res. 1999b;22:237.
Reichel H, Esser A, Roth HJ, Schmidt-Gayk H. Influence of PTH assay methodology on differenzial diagnosis of renal bone disease. Nephrol Dial Transplant. 2003;18:759-68.
Reichel H, Deibert B, Geberth S, Schmidt-Gayk H, Ritz E. Frusemide therapy and intact parathyroid hormone levels in chronic renal insufficiency. Nephrol Dial Transplant. 1992;7:8-15.
Reiss E, Canterbury JM, Bercovitz MA, Kaplan EL. The role of phosphate in the secretion of parathyroid hormone in man. J Clin Invest. 1970;49:2146-50.
Renaud H, Atik A, Herve M, et al. Evaluation of vascular calcinosis risk factors in patients on chronic hemodialysis - lack of influence of calcium carbonate. Nephron. 1988;48:28-32.
Rickers H, Nielsen AH, Smith-Pedersen R, Rodbro P. Bone mineral loss during maintenance hemodialysis. Acta Med Scand. 1978;204:263-70.
Ring T, Sodemann B, Nielsen C, Melsen F, Kornerup HJ. Mineralization defect but no effect of hypercalcemia during clodronate treatment in secondary hyperparathyroidism. Clin Nephrol. 1995;44:209-10.
Risteli J, Elomaa I, Niemi S, Novario A, Risteli L. Radioimmunoassay for the pyridinoline cross-linked carboxyterminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clin Chem. 1993;39:635-40.
Ritz E, Seidel A, Ramisch H, Szabo A, Boullion R. Attenuated rise of 1,25(OH)2 vitamin D3 in response to parathyroid hormone in patients with incipient renal failure. Nephron. 1991;57:314-8.
Ritz E, Kuster S, Schmidt-Gayk H, et al. Low-dose calcitriol prevents the rise in 1,84-iPTH without affecting serum calcium and phosphate in patients with moderate renal failure (prospective placebo-controlled multicentre trial). Nephrol Dial Transplant. 1995;10:2228-34.
Ritzerfeld M, Klasser M, Mann H. Alfacalcidol in the therapy of renal bone disease. Int J Clin Pharmacol Ther. 2001;39:546-50.
Rodriguez-Perez JC, Plaza C, Torres A, et al. Low turnover bone disease is the more common form of bone disease in CAPD patients. Adv Perit Dial. 1992;8:376-80.
Rostand SG, Drüeke TB. Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. Kidney Int. 1999;56:383-92.
Roussanne MC, Lieberherr M, Souberielle JC, Safati E, Drüeke TB, Bourdeau A. Human parathyroid cell proliferation in response to calcium, NPS R-467, calcitriol and phosphate. Eur J Clin Invest. 2001;31:610-6.
Rubin DA, Jüppner H. Zebrafish express the common parathyroid hormone/parathyroid hormone-related peptide receptor (PTH1R) and a novel receptor (PTH3R) that is preferentially activated by mammalian and fugufish parathyroid hormone-related peptide. J Biol Chem. 1999;274:28185-90.
Russell J, Lettieri D, Sherwood LM. Suppression by 1,25(OH) 2D3 of transcription of the pre-proparathyroid gene. Endocrinology. 1986;119:2864-6.
Salem MM. Hyperparathyroidism in the hemodialysis population: a survey of 612 patients. Am J Kidney Dis. 1997;29:862-5.
Salusky IB, Coburn JW, Brill J, et al. Bone disease in pediatric patients undergoing dialysis with CAPD or CCPD. Kidney Int. 1988;33:975-82.
Salusky IB, Ramirez JA, Oppenheim W, Gales B, Segre GV, Goodman WG. Biochemical markers of renal osteodystrophy in pediatric patients undergoing CAPD/CCPD. Kidney Int. 1994;45:253-8.
Salusky IB, Goodman WG, Kuizon BD, et al. Similar predictive value of bone turnover using first- and second-generation immunometric PTH assays in pediatric patients treated with peritoneal dialysis. Kidney Int. 2003;63:1801-8.
Sanchez CP, Goodman WG, Ramirez JA, et al. Calcium regulated parathyroid hormone secretion in adynamic renal osteodystrophy. Kidney Int. 1995;48:838-43.
Sanchez CP, Salusky IB, Kuizon BD, Abdella P, Jüppner H, Goodman WP. Growth of long bones in renal failure: roles of hyperparathyroidism, growth hormone and calcitriol. Kidney Int. 1998;54:1879-87.
Schmidt S, Chudek J, Karkoszka H, et al. The BsmI vitamin D-receptor polymorphism and secondary hyperparathyroidism. Nephrol Dial Transplant. 1997;12:1771-2.
Schomig M, Ritz E. Management of disturbed calcium metabolism in uraemic patients - 2. Indications for parathyroidectomy. Nephrol Dial Transplant. 2000;15[Suppl5]:25-9.
Schwalbe S, Holzhauer M, Schaeffer J, Galanski M, Koch KM, Floege J. Beta 2-microglobulin associated amyloidosis - a vanishing complication of long-term hemodialysis? Kidney Int. 1997;52:1077-83.
Sebert JL, Ruiz JC, Fournier A, et al. Plasma bone Gla-protein: assessment of its clinical value as an index of bone formation in hemodialyzed patients. Bone Miner. 1987;2:21-7.
Segre GV. Receptors for parathyroid hormone and parathyroid hormone-related protein. In: Bilezikian JP, Raisz LG, Rodan GA. Principles in Bone Biology. New York: Academic; 1996:377-403.
Seidel A, Herrmann P, Klaus G, Mehls O, Schmidt-Gayk H, Ritz E. Kinetics of plasma iPTH(1-84) after high dose of calcitriol in uremic patients. Clin Nephrol. 1993;39:210-3.
Sela-Brown A, Silver J, Brewer G, Naveh-Many T. Identification of AUF1 as a parathyroid hormone mRNA 3'-untranslated region-binding protein that determines parathyroid hormone mRNA stability. J Biol Chem. 2000;275:7424-9.
Sethi D, Naunton Morgan TC, Brown EA, Jewkes RF, Gower PE. Technetium-99-labelled methylene diphosphonate uptake scans in patients with dialysis arthropathy. Nephron. 1990;54:202-7.
Shearing CH, Ashby JP, Hepburn DA, Fisher BM, Frier BM. Suppression of plasma intact parathyroid hormone levels during insulin-induced hypoglycemia in humans. J Clin Endocrinol Metab. 1992;74:1270-6.
Sheikh MS, Maguire JA, Emmett M, et al. Reduction of dietary phosphorus absorption by phosphorus binders - A theoretical, in vitro, and in vivo study. J Clin Invest. 1989;83:66-73.
Sherrard DJ,Hercz G, Pei Y, et al. The spectrum of bone disease in end-stage renal failure - an evolving disorder. Kidney Int. 1993;43:436-42.
Shvil Y, Naveh-Many T, Barach P, Silver J. Regulation of parathyroid cell gene expression in experimental uremia. J Am Soc Nephrol. 1990;1:99-104.
Silver J, Russell J, Sherwood JM. Regulation by vitamin D metabolites of messenger ribonucleic acid for preproparathyroid hormone in isolated bovine parathyroid cells. Proc Natl Acad Sci USA. 1985;82:4270-3.
Silver J, Naveh-Many T, Mayer H, Schmelzer HJ, Popovtzer MM. Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo in the rat. J Clin Invest. 1986;78:1296-301.
Silver J, Yalcindag C, Sela-Brown A, Kilav R, Naveh-Many T. Regulation of the parathyroid hormone gene by vitamin D, calcium and phosphate. Kidney Int. 1999;73[Suppl]:S2-7.
Silver J. Molecular mechanisms of secondary hyperparathyroidism. Nephrol Dial Transplant. 2000;15[Suppl5]:S2-7.
Silverberg SJ, Bone HG, Marriott TB, et al. Short-term inhibition of parathyroid hormone secretion by a calcium-receptor agonist in patients with primary hyperparathyroidism. N Engl J Med. 1997;337:1506-10.
Simoes J, Barata JD, D'Haese PC, De Broe ME. Cela n'arrive qu'aux autres (aluminium intoxication only happens in the other nephrologist's dialysis centre) Nephrol Dial Transplant. 1994;9:67-8.
Slatopolsky E, Finch J, Denda M, et al. Phosphate restriction prevents parathyroid cell growth in uremic rats - High phosphate directly stimulates PTH secretion in vitro. J Clin Invest. 1996;97:2534-40.
Slatopolsky E. The role of calcium, phosphorus and vitamin D metabolism in the development of secondary hyperparathyroidism. Nephrol Dial Transplant. 1998;13:3-8.
Slatopolsky E., Burke SK, Dillon MA. RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone (The RenaGel Study Group). Kidney Int. 1999;55:299-307.
Slatopolsky E, Finch J, Clay P, et al. A novel mechanism for skeletal resistance in uremia. Kidney Int. 2000;58:753-61.
Smogorzewski M, Zayed M, Zhang YB, Roe J, Massry SG. Parathyroid hormone increases cytosolic calcium concentration in adult rat cardiac myocytes. Am J Physiol. 1993;264:H1998-2006.
Stefanovic V, Mitic M, Golubovic E, Rajic M, Avramovic V, Ignjatovic I. Transperitoneal removal of osteocalcin, calcitonin and parathyroid hormone in patients treated by CAPD. Nephron. 1996;74:216-7.
Stehman-Breen CO, Sherrard DJ, Alem MM, et al. Risk factors for hip fracture among patients with end-stage renal disease. Kidney Int. 2000;58:2200-5.
Stein MS, Packham DK, Ebeling PR, et al. Prevalence and risk factors for osteopenia in dialysis patients. Am J Kidney Dis. 1996;28:515-22.
Stern PH, De Olazabal J, Bell NH. Evidence for abnormal regulation of circulating 1 ,25-dihydroxyvitamin D in patients with sarcoidosis and normal calcium metabolism. J Clin Invest. 1980;66:852-5.
Stracke S, Jehle PM, Sturm D, et al. Clinical course after total parathyroidectomy without autotransplantation in patients with end-stage renal failure. Am J Kidney Dis. 1999;33:304-11.
Sugimoto T, Ritter C, Morrissey J, Hayes C, Slatopolsky E. Effects of high concentrations of glucose on PTH secretion in parathyroid cells. Kidney Int. 1990;37:1522-7.
Szabo A, Merke J, Beier E, Mall G, Ritz E. 1,25(OH) vitamin D3 inhibits parathyroid cell proliferation in experimental uremia. Kindey Int. 1989;35:1049-56.
Tamashiro M, Iseki K, Sunagawa O, et al. Significant association between the progression of coronary artery calcification and dyslipidemia in patients on chronic hemodialysis. Am J Kidney Dis. 2001;38:64-9.
Tian J, Smogorzewski M, Kedes L, Massry SG. PTH-PTHrP receptor mRNA is down-regulated in chronic renal failure. Am J Nephrol. 1994;14:41-6.
Tintut Y, Demer LL. Recent advances in multifactorial regulation of vascular calcification. Curr Opin Lipidol. 2001;12:555-60.
Tokumoto M, Tsuruya K, Fukada K, Kanai H, Kuroki S, Hirakata H. Reduced p21, p27 and vitamin D receptor in the nodular hyperplasia in patients with advanced secondary hyperparathyroidism. Kidney Int. 2002;62:1196-207.
Tokuyama T, Ikeda T, Sato K, Mimura O, Morita A, Tabata T. Conjunctival and corneal calcification and bone metabolism in hemodialysis patients. Am J Kidney Dis. 2002;39:291-6.
Tominaga Y, Grimelius L, Falkner U, Johanson H, Falkner S. DNA ploidy pattern of parathyroid parenchymal cells in renal secondary hyperparathyroidism with relapse. Anal Cell Pathol. 1991;3:325-33.
Tominaga Y, Kohara S, Namii Y, et al. Clonal analysis of nodular parathyroid hyperplasia in renal hyperparathyroidism. World J Surg. 1996;20:744-52.
Tominaga Y, Tanaka Y, Sato K, et al. Recurrent renal hyperparathyroidism and DNA analysis of autografted parathyroid tissue. World J Surg. 1992;16:595-603.
Tominaga Y, Tsuzuki T, Uchida K, et al. Expression of PRAD1/cyclin D1, retinoblastoma gene products, and Ki67 in parathyroid hyperparathyroidism caused by chronic renal failure versus primary adenoma. Kidney Int. 1999;55:1375-83.
Torres A, Lorenzo V, Hernandez D, et al. Bone disease in predialysis, hemodialysis, and CAPD patients: Evidence of a better response to PTH. Kidney Int. 1995;47:1434-42.
Torres A, Machado M, Concepcion MT, et al. Influence of vitamin D receptor genotype on bone mass changes after renal transplantation. Kidney Int. 1996;50:1726-33.
Torres A, Hernandez D, Barros N, Rodriguez M, Lorenzo V, Felsenfeld AJ. Decreased osteoblast response to PTH as a predisposing factor for adynamic bone disease (ABD) in older dialysis patients. J Am Soc Nephrol. 1998;9:550A.
Ueda M, Inaba M, Okuno S, et al. Clinical usefulness of the serum N-terminal propeptide of type I collagen as a marker of bone formation in hemodialysis patients. Am J Kidney Dis. 2002;40:802-9.
Urena P, Kong XF, Abou-Samra AB, et al. Parathyroid hormone (PTH)/PTH-related peptide receptor messenger ribonucleic acids are widely distributed in rat tissues. Endocrinology. 1993;133:617-23.
Urena P, Kubrusly M, Mannstadt M, et al. The renal PTH/PTHrP receptor is down-regulated in rats with chronic renal failure. Kidney Int. 1994;45:605-11.
Urena P, Ferreira A, Kung VT, et al. Serum pyridinoline as a specific marker of collagen breakdown and bone metabolism in hemodialysis patients. J Bone Min Res. 1995;10:932-9.
Urena P, Ferreira A, Morieux C, Drüeke TB, de Vernejoul MC. PTH/PTHrP receptor mRNA is down-regulated in epiphyseal cartilage growth plate of uremic rats. Nephrol Dial Transplant. 1996;11:2008-16.
Urena P, Hruby M, Ferreira A, Ang KS, de Vernejoul MC. Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients. J Amer Soc Nephrol. 1996;7:506-12.
Usdin TB, Gruber C, Bonner TI. Identification and functional expression of a receptor selectively recognizing parathyroid hormone, the PTH-2 receptor. J Biol Chem. 1995;270:15455-8.
Usdin TB, Bonner TI, Harta G, Mezey E. Distribution of parathyroid hormone-2 receptor messenger RNA in rat. Endocrinology. 1996;137:4285-97.
Venkataraman PS, Han BK, Tsang RC, Daugherty CC. Secondary hyperparathyroidism and bone disease in infants receiving long term furosemide therapy. Am J Dis Child. 1983;137:1157-61.
Vincenti F, Arnaud SB, Recker R, et al. Parathyroid and bone response of the diabetic patient to uremia. Kidney Int. 1984;25:677-82.
Wallfeldt C, Gylfe E, Larsson R, Ljunghall S, Rastad J, Akerstrom G. Relationship between external and cytoplasmic calcium concentrations, parathyroid hormone release and weight of parathyroid glands in human hyperparathyroidism. J Endocrinol. 1988;116:457-64.
Wayhs R, Zelinger A, Raggi P. High coronary artery calcium scores pose an extremely elevated risk for hard events. J Am Coll Cardiol. 2002;39:225-30.
Weinreich T, Passlick-Deetjen J, Ritz E. Low dialysate calcium in continuous ambulatory peritoneal dialysis: a randomized controlled multicenter trial (The Peritoneal Dialysis Multicenter Study Group). Am J Kidney Dis. 1995;25:452-60.
Weinreich T, Zapf J, Schmidt-Gayk H, Ritzel H, Delling G, Reichel H. Insulin-like growth factor 1 and 2 serum concentrations in dialysis patients with secondary hyperparathyroidism and adynamic bone disease. Clin Nephrol. 1999;51:27-33.
Wilmer WA, Magro CM. Calciphylaxis: emerging concepts in prevention, diagnosis, and treatment. Semin Dial. 2002;15:172-86.
Wiske PS, Epstein S, Bell NH, Queener SF, Edmondson J, Johnston jr CC. Increases in immunoreactive parathyroid hormone with age. N Engl J Med. 1979;300:1419-21.
Yajima A, Tanaka K, Tominaga Y, et al. Early changes of bone histology and circulating markers of bone turnover after parathyroidectomy in hemodialysis patients with severe hyperparathyroidism. Clin Nephrol. 2001;56:27-34.
Yamamoto M, Igarashi T, Muramatsu M, Fukagawa M, Motokura T, Ogata E. Hypocalcemia increases and hypercalcemia decreases the steady-state level of parathyroid hormone messenger RNA in the rat. J Clin Invest. 1989;83:1053-6.
Yi H, Fukagawa M, Yamato H, Kumagai M, Watanabe T, Kuragawa K. Prevention of enhanced parathyroid hormone secretion, synthesis and hyperplasia by mild dietary phosphorus restriction in early chronic renal failure in rats - Possible direct role of phosphorus. Nephron. 1995;70:242-8.